NKGen Biotech

NKGen Biotech Capital Intensity

The Capital Intensity Ratio of NKGen Biotech (NKGN) as of Nov 22, 2026 is 21,207.79 %. In the previous year, Capital Intensity Ratio was 4,241.78 % — a change of 399.97% (higher).

Capital Intensity

21,207.79 %

YoY

399.97%

Last updated:

Capital Intensity Ratio of NKGen Biotech is 2022 21,207.79 % . Capital Intensity Ratio of NKGen Biotech was 2021 4,241.78 % . It decreases by 399.97% higher compared to the previous year.

The NKGen Biotech Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2021
4,241.78 USD
Jan 1, 2022
21,207.79 USD
The NKGen Biotech Capital Intensity history
YEARCapital IntensityYoY
21,207.79 %+399.97%
4,241.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Capital Intensity Ratio of NKGen Biotech is 21,207.79 % in 2022.

Capital Intensity Ratio of NKGen Biotech changed from 4,241.78 % to 21,207.79 %, representing a 399.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's NKGen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NKGen Biotech

All Key Metrics — NKGen Biotech